Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study.

Rudofsky G, Catarig AM, Favre L, Grau K, Häfliger S, Thomann R, Schultes B

Diabetes research and clinical practice1 Jul 2021Cited by 41 (Europe PMC)

PMID34217773DOI10.1016/j.diabres.2021.108931PepBankPUB-34217773

Summary

AimsSURE Switzerland (NCT03631186) investigated real-world once-weekly (OW) semaglutide use in adults with type 2 diabetes (T2D).MethodsThis multicentre, prospective, observational study enrolled adults with T2D with ≥ 1 documented HbA_1c value ≤ 12 weeks before semaglutide initiation. Primary endpoint was change in HbA_1c from baseline to end of study (EOS; ~30 weeks). Secondary endpoints included changes in body weight (BW) and waist circumference (WC), and the proportion of patients achieving HbA_1c < 8.0%, <7.5% and <7.0% at EOS. Semaglutide dose at EOS was a prespecified exploratory endpoint.ResultsOverall, 214 patients initiated semaglutide (baseline HbA_1c 7.8% [62 mmol/mol], BW 99.9 kg and WC 117.4 cm); 187 attended the EOS visit. At EOS, 175 (81.8%) were still receiving semaglutide (mean [SD] dose 0.78 [0.29] mg); in those patients, mean HbA_1c reduced by -0.8 [95% CI - 1.01;-0.68] %-points (-9 [-11;-7] mmol/mol), BW by -5.0 kg [-5.73;-4.24] and WC by -4.8 cm [-5.75;-3.79] (all p < 0.0001). At EOS, 85.9%, 76.5% and 55.9% patients achieved, respectively, HbA_1c < 8.0%, <7.5% and < 7.0%. No new safety signals were identified.ConclusionsPatients with T2D in Switzerland initiating OW semaglutide experienced clinically relevant glycaemic control and BW improvements in a real-world setting, supporting semaglutide use in routine clinical practice.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in Switzerland, once-weekly semaglutide lowered mean HbA1c by 0.8 percentage points (p < 0.0001).
In plain wordsIn adults with type 2 diabetes in Switzerland, once-weekly semaglutide was linked to a lower HbA1c, about 0.8 percentage points.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change from baseline to end of study
Study
n = 175
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
mean 0.78 mg at end of study · ~30 weeksAs given in this study (human).
Measurements
HbA1c change
−0.8 %-points
end of study
Source sentences
Summary
At EOS, 175 (81.8%) were still receiving semaglutide (mean [SD] dose 0.78 [0.29] mg); in those patients, mean HbA_1c reduced by -0.8 [95% CI - 1.01;-0.68] %-points (-9 [-11;-7] mmol/mol), BW by -5.0 kg [-5.73;-4.24] and WC by -4.8 cm [-5.75;-3.79] (all p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Primary endpoint was change in HbA_1c from baseline to end of study (EOS; ~30 weeks).
Summary · context
This multicentre, prospective, observational study enrolled adults with T2D with ≥ 1 documented HbA_1c value ≤ 12 weeks before semaglutide initiation.
Show in the study text Report a problemFND-3421777301
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in Switzerland, once-weekly semaglutide lowered body weight by 5.0 kg (p < 0.0001).
In plain wordsIn adults with type 2 diabetes in Switzerland, once-weekly semaglutide was linked to weight loss of about 5.0 kg.
Peptide
Semaglutide
Outcome
DecreaseBody weight change from baseline to end of study
Study
n = 175
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
mean 0.78 mg at end of study · ~30 weeksAs given in this study (human).
Measurements
Body weight change
−5 kg
end of study
Source sentences
Summary
At EOS, 175 (81.8%) were still receiving semaglutide (mean [SD] dose 0.78 [0.29] mg); in those patients, mean HbA_1c reduced by -0.8 [95% CI - 1.01;-0.68] %-points (-9 [-11;-7] mmol/mol), BW by -5.0 kg [-5.73;-4.24] and WC by -4.8 cm [-5.75;-3.79] (all p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints included changes in body weight (BW) and waist circumference (WC), and the proportion of patients achieving HbA_1c < 8.0%, <7.5% and <7.0% at EOS.
Summary · context
This multicentre, prospective, observational study enrolled adults with T2D with ≥ 1 documented HbA_1c value ≤ 12 weeks before semaglutide initiation.
Show in the study text Report a problemFND-3421777302
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in Switzerland, once-weekly semaglutide lowered waist circumference by 4.8 cm (p < 0.0001).
In plain wordsIn adults with type 2 diabetes in Switzerland, once-weekly semaglutide was linked to a smaller waist, by about 4.8 cm.
Peptide
Semaglutide
Outcome
DecreaseWaist circumference change from baseline to end of study
Study
n = 175
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
mean 0.78 mg at end of study · ~30 weeksAs given in this study (human).
Measurements
Waist circumference change
−4.8 cm
end of study
Source sentences
Summary
At EOS, 175 (81.8%) were still receiving semaglutide (mean [SD] dose 0.78 [0.29] mg); in those patients, mean HbA_1c reduced by -0.8 [95% CI - 1.01;-0.68] %-points (-9 [-11;-7] mmol/mol), BW by -5.0 kg [-5.73;-4.24] and WC by -4.8 cm [-5.75;-3.79] (all p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints included changes in body weight (BW) and waist circumference (WC), and the proportion of patients achieving HbA_1c < 8.0%, <7.5% and <7.0% at EOS.
Summary · context
This multicentre, prospective, observational study enrolled adults with T2D with ≥ 1 documented HbA_1c value ≤ 12 weeks before semaglutide initiation.
Show in the study text Report a problemFND-3421777303
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in Switzerland, 85.9% reached HbA1c below 8.0% at end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in Switzerland, 85.9% reached an HbA1c below 8.0% on once-weekly semaglutide.
Peptide
Semaglutide
Outcome
IncreaseProportion with HbA1c below 8.0%
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Proportion HbA1c <8.0%
85.9%
end of study
Source sentences
Summary
At EOS, 85.9%, 76.5% and 55.9% patients achieved, respectively, HbA_1c < 8.0%, <7.5% and < 7.0%.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints included changes in body weight (BW) and waist circumference (WC), and the proportion of patients achieving HbA_1c < 8.0%, <7.5% and <7.0% at EOS.
Summary · context
This multicentre, prospective, observational study enrolled adults with T2D with ≥ 1 documented HbA_1c value ≤ 12 weeks before semaglutide initiation.
Show in the study text Report a problemFND-3421777304
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in Switzerland, 76.5% reached HbA1c below 7.5% at end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in Switzerland, 76.5% reached an HbA1c below 7.5% on once-weekly semaglutide.
Peptide
Semaglutide
Outcome
IncreaseProportion with HbA1c below 7.5%
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Proportion HbA1c <7.5%
76.5%
end of study
Source sentences
Summary
At EOS, 85.9%, 76.5% and 55.9% patients achieved, respectively, HbA_1c < 8.0%, <7.5% and < 7.0%.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints included changes in body weight (BW) and waist circumference (WC), and the proportion of patients achieving HbA_1c < 8.0%, <7.5% and <7.0% at EOS.
Summary · context
This multicentre, prospective, observational study enrolled adults with T2D with ≥ 1 documented HbA_1c value ≤ 12 weeks before semaglutide initiation.
Show in the study text Report a problemFND-3421777305
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in Switzerland, 55.9% reached HbA1c below 7.0% at end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in Switzerland, 55.9% reached an HbA1c below 7.0% on once-weekly semaglutide.
Peptide
Semaglutide
Outcome
IncreaseProportion with HbA1c below 7.0%
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Proportion HbA1c <7.0%
55.9%
end of study
Source sentences
Summary
At EOS, 85.9%, 76.5% and 55.9% patients achieved, respectively, HbA_1c < 8.0%, <7.5% and < 7.0%.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints included changes in body weight (BW) and waist circumference (WC), and the proportion of patients achieving HbA_1c < 8.0%, <7.5% and <7.0% at EOS.
Summary · context
This multicentre, prospective, observational study enrolled adults with T2D with ≥ 1 documented HbA_1c value ≤ 12 weeks before semaglutide initiation.
Show in the study text Report a problemFND-3421777306
07HumanObservational studySafety outcome
In adults with type 2 diabetes in Switzerland, no new safety signals were identified with once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in Switzerland, no new safety signals appeared with once-weekly semaglutide.
Peptide
Semaglutide
Outcome
Not applicableSafety signals
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Source sentences
Summary
No new safety signals were identified.
1 context sentence(design, population, supporting numbers)
Summary · context
This multicentre, prospective, observational study enrolled adults with T2D with ≥ 1 documented HbA_1c value ≤ 12 weeks before semaglutide initiation.
Show in the study text Report a problemFND-3421777307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT03631186

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)

Novo Nordisk A/Sn = 21512 Sept 2018 to 18 Dec 2019

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 28 Jul 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.